NCT03954704 - Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

October 27, 2020

Study Completion Date

April 15, 2021

Conditions

Advanced Solid Tumors

Interventions

DRUG

Dalutrafusp alfa

Administered intravenously

DRUG

mFOLFOX6 Regimen

Chemotherapy regimen of oxaliplatin, 5-fluorouracil \[5-FU\], and leucovorin

DRUG

Dalutrafusp alfa

Administered intravenously

Trial Locations (4)

Mary Crowley Cancer Research, Dallas

NEXT Oncology, San Antonio

Scottsdale Healthcare Hospitals d/b/a HonorHealth, Scottsdale

Beth Israel Deaconess Medical Center, Boston